全文获取类型
收费全文 | 122911篇 |
免费 | 12029篇 |
国内免费 | 5569篇 |
学科分类
医药卫生 | 140509篇 |
出版年
2024年 | 161篇 |
2023年 | 1865篇 |
2022年 | 2611篇 |
2021年 | 5022篇 |
2020年 | 4341篇 |
2019年 | 4201篇 |
2018年 | 3969篇 |
2017年 | 4465篇 |
2016年 | 4863篇 |
2015年 | 5436篇 |
2014年 | 7969篇 |
2013年 | 7643篇 |
2012年 | 7197篇 |
2011年 | 7739篇 |
2010年 | 6278篇 |
2009年 | 6269篇 |
2008年 | 6430篇 |
2007年 | 6772篇 |
2006年 | 6261篇 |
2005年 | 5598篇 |
2004年 | 4495篇 |
2003年 | 3999篇 |
2002年 | 3431篇 |
2001年 | 3166篇 |
2000年 | 2713篇 |
1999年 | 2206篇 |
1998年 | 1995篇 |
1997年 | 1823篇 |
1996年 | 1635篇 |
1995年 | 1383篇 |
1994年 | 1290篇 |
1993年 | 949篇 |
1992年 | 841篇 |
1991年 | 781篇 |
1990年 | 631篇 |
1989年 | 553篇 |
1988年 | 511篇 |
1987年 | 411篇 |
1986年 | 351篇 |
1985年 | 432篇 |
1984年 | 333篇 |
1983年 | 242篇 |
1982年 | 283篇 |
1981年 | 231篇 |
1980年 | 210篇 |
1979年 | 163篇 |
1978年 | 118篇 |
1977年 | 89篇 |
1976年 | 70篇 |
1975年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
目的:探讨MRI在浸润性小叶癌(ILC)术前诊断中的应用价值,并评估乳腺密度对其影响。方法:选取75例术前30天内行MRI检查的I-Ⅲ期ILC患者列入本项研究,根据腺体含量评估乳腺密度,在MRI下测量肿瘤大小,并对比其与病理大小的一致性。结果:75例入组患者中26例(34.7%)患者经MRI评估发现新的可疑病灶,20例(26.7%)患者改变了手术方式。高密度乳腺型患者额外病灶检出率明显高于低密度乳腺型患者(51.6% vs 22.7%,P=0.010)。MRI评估肿瘤大小在低密度乳腺型患者中容易被低估(36.4% vs 12.9%,P=0.024),在高密度乳腺型患者中容易被高估(6.8% vs 29.0%,P=0.010),但两组患者与病理大小一致性的比例无明显差异。结论:ILC患者术前乳腺MRI检查能够提高额外恶性肿瘤的检出率,而乳腺密度是影响MRI评估的重要因素。 相似文献
42.
43.
44.
《Journal of the American College of Radiology》2020,17(10):1207-1219
PurposeLobular neoplasia (LN) detected on breast core needle biopsy is frequently managed with surgical excision because of concern for undersampled malignancy. The authors performed a systematic review and meta-analysis to estimate the risk for upgrade to malignancy in the setting of imaging-concordant classic LN diagnosed on core biopsy.MethodsPubMed and Embase were searched for original articles published from 1998 to 2020 that reported rates of upgrade to malignancy for classic LN, including atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ (LCIS). Two reviewers extracted study data and assessed the following quality criteria: exclusion of variant LCIS, exclusion of imaging-discordant lesions, and outcome reporting for ≥70% of lesions. For studies meeting all criteria, pooled risks for upgrade to any malignancy (invasive carcinoma or ductal carcinoma in situ) and invasive malignancy for all LN, ALH, and LCIS were estimated using random-effects models.ResultsFor 65 full-text articles included in the review, the risk for upgrade to any malignancy ranged from 0% to 45%. Among the 16 studies that met all quality criteria for the meta-analysis, pooled risks for upgrade to any malignancy were 3.1% (95% confidence interval [CI], 1.8%-5.2%) for all LN, 2.5% (95% CI, 1.6%-3.9%) for ALH, and 5.8% (95% CI, 2.9%-11.3%) for LCIS. Risks for upgrade to invasive malignancy were 1.3% (95% CI, 0.7%-2.4%) for all LN, 0.4% (95% CI, 0.0%-4.2%) for ALH, and 3.5% (95% CI, 2.0%-5.9%) for LCIS.ConclusionsThe risk for upgrade to malignancy for LN found on breast biopsy is low. Imaging surveillance can likely be offered as an alternative to surgical management for LN, particularly for ALH. 相似文献
45.
46.
Hui-Ju Ch’ang 《World journal of hepatology》2015,7(16):2029-2040
The success of sorafenib in prolonging survival of patients with hepatocellular carcinoma (HCC) makes therapeutic inhibition of angiogenesis a component of treatment for HCC. To enhance therapeutic efficacy, overcome drug resistance and reduce toxicity, combination of antiangiogenic agents with chemotherapy, radiotherapy or other targeted agents were evaluated. Nevertheless, the use of antiangiogenic therapy remains suboptimal regarding dosage, schedule and duration of therapy. The issue is further complicated by combination antiangiogenesis to other cytotoxic or biologic agents. There is no way to determine which patients are most likely respond to a given form of antiangiogenic therapy. Activation of alternative pathways associated with disease progression in patients undergoing antiangiogenic therapy has also been recognized. There is increasing importance in identifying, validating and standardizing potential response biomarkers for antiangiogenesis therapy for HCC patients. In this review, biomarkers for antiangiogenesis therapy including systemic, circulating, tissue and imaging ones are summarized. The strength and deficit of circulating and imaging biomarkers were further demonstrated by a series of studies in HCC patients receiving radiotherapy with or without thalidomide. 相似文献
47.
Sevim Turanli Nazan Bozdogan Hakan Mersin Ugur Berberoglu 《The Indian journal of surgery》2015,77(6):489-494
Helicobacter pylori has been associated with diverse pathologies of varying severity. We investigated the H. pylori infection status and its association with the pathologic features and clinical outcomes in stage III gastric cancer patients treated with adjuvant therapy after curative resection. Between 2004 and 2009, the records of 76 consecutive patients were retrospectively reviewed. H. pylori infection was confirmed by examination of pathological specimen. The relationship between H. pylori and the clinicopathological features was analyzed by Fisher exact test, Student’s t test, and Kaplan-Meier method. Of the 76 patients, 16 patients (21.1 %) were confirmed for H. pylori infection. The median age was 59 years. Twenty-three patients received chemotherapy and remainder received chemoradiotherapy. H. pylori status did not correlate with the clinicopathologic features. It was greater in non-neoplastic tissue than the tumor tissue (21.1 vs 7.9 %). Median follow-up was 21 months. During this period, 88.2 % patients had experienced tumor recurrence, and 85.5 % patients had died. Recurrence was observed in 87.5 % patients and in 88.3 % patients in H. pylori-positive and H. pylori-negative patients, respectively (P = 0.92). Disease-free survival was 28.4 ± 7.9 months and overall survival was 31.5 ± 7.4 months in H. pylori-positive patients compared with 28.3 ± 3.7 and 33.2 ± 3.4 months, respectively, in H. pylori-negative patients. H. pylori infection status did not have effect on the overall or disease-free survival (p = 0.85 and P = 0.86), respectively. H. pylori status might not be useful as a prognostic and predictive factor for clinical outcomes. 相似文献
48.
49.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis 下载免费PDF全文
50.